NASDAQ · QNTM
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for QNTM: Nov 6, 2026
Quantum Biopharma Ltd. Class B Subordinate Voting Shares is estimated to report earnings on 11/06/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-1.25.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · RTTNews · Fintel- MarketBeat · Oct 14, 9:50 AM EDTQuantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets BuiltArtificial intelligence (AI) is compressing parts of drug discovery from years into, in some cases, minutes. The regulatory clock has not sped up to match. That gap is where biotech investors win or lose. A lab breakthrough is still only a candidate until it clears human trials
- RTTNews · Oct 6, 6:31 AM EDTQuantum BioPharma Advances Lucid-MS Into Phase 2 Development With Thermo Fisher Partnership(RTTNews) – Quantum BioPharma Ltd. (QNTM) has signed a study start-up agreement with clinical research business of Thermo Fisher Scientific's PPD Clinical Research Business to implement its Phase 2 clinical trial of Lucid-MS, a treatment for multiple sclerosis.
- RTTNews · Sep 9, 2:36 PM EDTClinical Catalysts Drive Biotech Movers: Opus Genetics, Quantum & More(RTTNews) – Biotech and medical device stocks saw notable moves Wednesday, led by Opus Genetics, which surged more than 27% following positive clinical data. Quantum BioPharma gained after receiving FDA clearance for a Phase 2 MS trial, while Pulse Biosciences rallied more than 1
- RTTNews · Sep 9, 10:14 AM EDTQuantum BioPharma Receives FDA Clearance For Lucid-MS Phase 2 Trial(RTTNews) – Quantum BioPharma Ltd. (QNTM) announced that the U.S. Food and Drug Administration (FDA) has cleared the company to begin a Phase 2 clinical trial evaluating Lucid-MS, its investigational treatment for multiple sclerosis (MS).
- RTTNews · Aug 10, 7:47 AM EDTQuantum: FDA Approves IND For Lucid-MS; To Engage CRO To Support Implementation Of Phase 2 Study(RTTNews) – Quantum BioPharma (QNTM) announced the FDA has approved the company's Investigational New Drug application for Lucid-MS, enabling Quantum BioPharma to immediately advance its patented, multiple sclerosis program into Phase 2 clinical development. The company said it i
- Fintel · Apr 28, 11:06 AM EDTQuantum BioPharma (QNTM) Price Target Increased by 10.88% to 36.72The average one-year price target for Quantum BioPharma (NasdaqCM:QNTM) has been revised to $36.72 / share. This is an increase of 10.88% from the prior estimate of $33.12 dated April 14, 2026. The price target is an average of many targets provided by analyst
- RTTNews · Apr 1, 10:16 AM EDTQuantum BioPharma Submits IND To FDA For Lucid-MS In Multiple Sclerosis For Phase 2 Trial; Stock Up(RTTNews) – Quantum BioPharma Ltd. (QNTM), a biopharmaceutical company, on Wednesday announced that it has submitted an Investigational New Drug IND application to the U.S. Food and Drug Administration FDA for Lucid-21-302, also known as Lucid-MS, its new drug candidate for the t
- RTTNews · Dec 21, 11:20 PM ESTFriday's After-Hours Gainers: Biotech And Genomics Stocks Show Strength(RTTNews) – Several biotechnology and life sciences companies posted notable gains in after-hours trading on Friday, reflecting investor interest in recent clinical and corporate developments.
- RTTNews · Nov 28, 2:58 AM ESTQuantum Biopharma's $700 Mln Market Manipulation Case Featured In CTV W5 Investigative Series(RTTNews) – Quantum BioPharma Ltd. (QNTM), a Toronto-based biotechnology company, has filed a USD $700 million lawsuit alleging stock market manipulation that it says nearly derailed its promising Lucid-MS research targeting multiple sclerosis candidates. The case is now the subj
- RTTNews · Nov 26, 1:46 PM ESTQuantum BioPharma Shares Surge 32% After Lawsuit Investigation News Coverage(RTTNews) – Quantum BioPharma Ltd. (QNTM) leapt 32.09%, rising $2.58 to $10.62, after media reports highlighted a $700 million lawsuit accusing the company of stock market manipulation, a case that has become the subject of a three-part investigative news series on W5.
- RTTNews · Aug 5, 9:43 AM EDTQuantum BioPharma Announces Positive Findings From Clinical Study Report Of Lucid-MS(RTTNews) – Quantum BioPharma Ltd. (QNTM), Tuesday announced that the company has received the clinical study report for the phase 1 multiple ascending dose trial of experimental multiple sclerosis drug Lucid-MS dosing in healthy adult participants.
- RTTNews · Jul 22, 8:37 AM EDTQuantum BioPharma Buys Shares Of GameStop(RTTNews) – Quantum BioPharma Ltd. (QNTM), Tuesday announced the purchase of 2,000 shares of GameStop Corp. (GME), making a strategic move in line with the company's commitment to combating market corruption and enhancing shareholder value.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Quantum Biopharma Ltd. Class B Subordinate Voting Shares from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.